ERBB2 and gastric cancer: Importantly, HApt-tFNA@Dxd demonstrated minimal adverse effects on normal tissues and vital organs while displaying heightened antitumor efficacy against HER2-positive gastric cancer when compared to the administration of free Dxd and tFNA@Dxd in NCI-N87 tumor-bearing mice [229].